DENTSPLY SIRONA (NASDAQ:XRAY) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) posted its earnings results on Thursday. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01), Zacks reports. DENTSPLY SIRONA had a positive return on equity of 17.10% and a negative net margin of 24.34%.

DENTSPLY SIRONA Price Performance

Shares of XRAY traded down $0.09 during mid-day trading on Thursday, hitting $12.71. 6,803,858 shares of the stock were exchanged, compared to its average volume of 4,690,824. The firm has a 50-day moving average of $12.32 and a two-hundred day moving average of $12.47. DENTSPLY SIRONA has a 52-week low of $9.85 and a 52-week high of $19.03. The company has a market cap of $2.54 billion, a PE ratio of -2.88, a price-to-earnings-growth ratio of 1.03 and a beta of 1.01. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.99 and a current ratio of 1.47.

DENTSPLY SIRONA Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is -14.48%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on XRAY. Zacks Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. lowered their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, January 5th. Finally, Barclays began coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They set an “underweight” rating and a $12.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.46.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after acquiring an additional 92,868 shares during the period. State Street Corp lifted its position in shares of DENTSPLY SIRONA by 5.5% during the second quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock worth $113,868,000 after purchasing an additional 369,876 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after purchasing an additional 5,234,587 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.